Ping An Biomedical Co., Ltd.

Ping An Biomedical Co., Ltd.

NNASDAQ:PASW
1.42
USD
-0.11
(-7.52%)
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.24
5.59
4.03
4.27
73.92
- -
Basic EPS, GAAP
0.38
0.35
-0.05
-0.06
-27.77
- -
Free Cash Flow per Basic Share
-2.28
1.03
-0.3
0.71
-13.91
- -
Dividend per Share
- -
0.24
0.47
0.02
- -
- -
Book Value per Share
-0.1
0.22
-0.29
-0.35
2.21
-0.35
Tangible Book Value per Share
-0.1
0.22
-0.29
-0.35
2.21
-0.35
Basic Weighted Avg Shares
14
21
21
21
- -
21
Sales/Revenue/Turnover
100
115
83
88
34
- -
Operating Margin (%)
9.06
9.73
0.74
- -
-43.05
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
5
7
-1
-1
-13
- -
Effective Tax Rate (%)
33.32
24.92
2,484.34
- -
- -
- -
Profit Margin (%)
5.24
6.31
-1.2
-1.47
-37.57
- -
Working Capital
-5
2
-9
-10
41
-10
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
-2
5
-6
-7
45
-7
Return on Invested Capital (%)
- -
33.63
-49.85
- -
- -
- -
Return on Capital (%)
- -
25.06
-109.98
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Mar'24
Sep'24
ST Debt
43
13
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
- -
- -
- -

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Mar'24
Sep'24
Total Current Assets
77
76
53
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
47
60
40
Inventories
3
2
- -
Total Current Liabilities
86
84
64
Payables & Accruals
42
71
52
ST Debt
43
13
10
Deferred Revenue
1
- -
2

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-729.39%
Free Cash Flow
- -
- -
-143.93%
Net Income, GAAP
- -
- -
899.03%
Sales/Revenue/Turnover
- -
- -
-61.03%
Total Cash Common Dividend
- -
- -
-100%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
83
2024
- -
- -
88
2025
- -
- -
34

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.05
2024
- -
- -
-0.06
2025
- -
- -
-27.77

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.47
2024
- -
- -
0.02
2025
- -
- -
- -

Company Description

CEO
Pi Jun Liu
Full Time Employees
7
Sector
Distribution services
Industry
Wholesale distributors
Address
China United Plaza Hong Kong Hong Kong
IPO Date
Jul 18, 2025
Business
Ping An Biomedical Co., Ltd. (NASDAQ:PASW) operates as an investment holding company that, through its subsidiaries, provides supply chain management services in the apparel industry in China; its services encompass market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The company offers a broad range of yarn products, textiles, and finished garments to brand owners, textile manufacturers, apparel sourcing agents, and online fashion and garment retailers; it also provides real estate property investment and warehousing services. Incorporated in 2021 and headquartered at China United Plaza, 22nd Floor, Cheung Sha Wan, Hong Kong, Ping An Biomedical is a subsidiary of Action Holdings Limited and employs seven people, with operations focused primarily in China. In September 2025, the company changed its name from Majestic Ideal Holdings Limited to Ping An Biomedical Co., Ltd.; in July 2025, it appointed Lina Jiang as Chief Executive Officer, succeeding prior leadership. These recent developments reflect strategic rebranding and executive enhancements amid ongoing apparel sector activities.

Company News

  • Ping An Biomedical Enters into Patent Purchase Agreement with Future Biotechnology Group for Tumor Cell Technologies

  • Ping An Biomedical Announces Planned Acquisition of Three Tumor Cell-Related Medical Technology Patents to Build a Core Oncology and Biotech Intellectual Property Portfolio

  • Ping An Biomedical Announces 1-for-40 Reverse Stock Split

  • Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years

  • All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital

  • Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry

  • Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation

  • Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter